NEW YORK — Quanterix took another step toward the diagnostics market last week with an agreement to license its high-sensitivity immunoassay technology to Abbott Laboratories.
The non-exclusive license allows Abbott to incorporate Quanterix's Simoa technology into its in vitro diagnostic platforms in exchange for an initial $10 million license fee, milestone fees subject to the achievement by Abbott of development, regulatory, and launch milestones, and royalties on the sales of licensed products.